{
 "as_of": "2026-11-06",
 "cmr": "ca-cm-kg/TSX/FRX",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# Fennec Pharmaceuticals Inc. (TSX: FRX) — research page\n\nAs of 2026-11-06 · ca-cm-kg · record version 1\n\n## Identity and listing\n\nFennec Pharmaceuticals Inc. is listed on the TSX under ticker FRX, with LEI 5299003IE70ITO2CBM73; no ISIN is on the record. The security type is Corporate, the sector is Life Sciences, and the jurisdiction is British Columbia. The segment is not on the record. The issuer is listed, not halted.\n\n## The disclosure read\n\nThe record holds 16 filings in the twelve months to 2026-11-06, across 12 filing days, all of them newswire releases. The median gap between filing days is 13 days. The latest filing is dated 2026-11-06, a newswire release, and is 0 days before the record date. The TSX median cadence gap is 16 days across 2,270 issuers, with a median of 0.0 filings and a median latency of 3.0 days. The Life Sciences median cadence gap is 17.5 days across 200 issuers, with a median of 7.0 filings and a median latency of 14 days.\n\n## Auditor\n\nThe auditor of record is Haskell & White LLP; its location is not on the record. The record holds no auditor changes.\n\n## Events and halts\n\nThe record holds no listing, delisting, name change, domicile change or segment move events. The halt flag is listed, not halted.\n\n## Orderability\n\nUnder rule version acm-68000/ca/kyp-know-your-product-ni-31-103/r1, the outcome for the client category Paragraph (o) of the definition is signal ACM-200, determinable. The outcome for the client category Paragraph (q) of the definition is signal ACM-200, determinable. The chapter is as of 2026-11-04.\n\n## Coverage\n\nThe field has not been read, so the number of research houses named on the issuer's investor-relations page is not on the record.\n\n## Open research\n\nThe field has not been read, so the count of openly published research notes is not on the record.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe record holds no sealed vintage for this market, and no sealed issuer years are on the record. The live record began on 2026-09-10. Years 2021 through 2026 are sealed in the store but not served as of a date; the as-of door answers not_sealed.\n\n## Sources\n\n8 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://www.tsx.com/json/company-directory/search/tsx/^* (identity.exchange)\n- https://api.gleif.org/api/v1/lei-records/5299003IE70ITO2CBM73 (identity.jurisdiction)\n- https://www.tsx.com/en/resource/571 (identity.sector)\n- https://mcp.ca-cm-kg.ai/events/TSX/FRX (the disclosure lines)\n- https://iiroc.mediaroom.com/index.php?s=2429&l=100 (the halt flag)\n- https://www.sec.gov/Archives/edgar/data/1211583/000114420417029188/v467708_def14a.htm (the auditor)\n- https://mcp.ca-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://mcp.ca-cm-kg.ai/record/TSX/FRX (the record)\n",
 "market": "CA",
 "node": "ca-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [],
   "live_record_began": "2026-09-10",
   "node_history_from": null,
   "node_years_sealed": [],
   "note": "6 years are sealed in the CA store; their Replay split is not built, so the as-of door answers not_sealed and the record is the live record as of 2026-11-06",
   "record_version": 1,
   "sealed": false,
   "store_years_sealed_not_served": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ]
  },
  "auditor": {
   "auditor": {
    "read_by": "Tavily regex",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1211583/000114420417029188/v467708_def14a.htm",
    "state": "sourced",
    "value": "Haskell & White LLP"
   },
   "auditor_firm_id": {
    "market": "CA",
    "state": "not_on_record"
   },
   "auditor_location": {
    "market": "CA",
    "state": "not_on_record"
   },
   "changes": []
  },
  "cmr": "ca-cm-kg/TSX/FRX",
  "coverage": {
   "note": "the coverage field has not been read for this issuer",
   "state": "not_read"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 2270,
     "median_cadence_gap_days": 16,
     "median_filings": 0,
     "median_latency_days": 3,
     "name": "TSX"
    },
    "sector": {
     "issuers": 200,
     "median_cadence_gap_days": 17.5,
     "median_filings": 7,
     "median_latency_days": 14,
     "name": "Life Sciences"
    }
   },
   "by_type": {
    "newswire_release": 16
   },
   "cadence_median_gap_days": 13,
   "filing_days": 12,
   "filings": 16,
   "latency_days": 0,
   "latest": [
    {
     "category": null,
     "date": "2026-11-06",
     "source": "https://www.globenewswire.com/news-release/2026/11/06/3397376/0/en/fennec-pharmaceuticals-to-report-third-quarter-2026-financial-results-on-november-12-2026.html",
     "title": "Fennec Pharmaceuticals to Report Third Quarter 2026",
     "type": "newswire_release"
    },
    {
     "category": null,
     "date": "2026-09-17",
     "source": "https://www.globenewswire.com/news-release/2026/09/17/3363875/0/en/fennec-pharmaceuticals-announces-oral-presentation-of-detailed-results-from-investigator-initiated-phase-2-sts-j01-clinical-study-of-pedmark-in-japan-at-siop-2026.html",
     "title": "Fennec Pharmaceuticals Announces Oral Presentation of",
     "type": "newswire_release"
    },
    {
     "category": null,
     "date": "2026-03-31",
     "source": "https://www.globenewswire.com/news-release/2026/03/31/3265241/0/en/Fennec-Pharmaceuticals-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html",
     "title": "Fennec Pharmaceuticals Announces Inducement Grants Under",
     "type": "newswire_release"
    },
    {
     "category": null,
     "date": "2026-03-18",
     "source": "https://www.globenewswire.com/news-release/2026/03/18/3258049/0/en/Fennec-Pharmaceuticals-to-Report-Full-Year-and-Fourth-Quarter-2025-Financial-Results-on-March-24-2026.html",
     "title": "Fennec Pharmaceuticals to Report Full Year and Fourth",
     "type": "newswire_release"
    },
    {
     "category": null,
     "date": "2026-03-04",
     "source": "https://www.globenewswire.com/news-release/2026/03/04/3249229/0/en/fennec-pharmaceuticals-announces-clinical-research-collaboration-with-tampa-general-hospital-cancer-institute.html",
     "title": "Fennec Pharmaceuticals Announces Clinical Research",
     "type": "newswire_release"
    }
   ],
   "latest_filing_date": "2026-11-06",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.ca-cm-kg.ai/events/TSX/FRX",
   "window": {
    "from": "2025-11-06",
    "to": "2026-11-06"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "tsx.com company directory (exchange list)",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://www.tsx.com/json/company-directory/search/tsx/^*",
    "state": "sourced",
    "value": "TSX"
   },
   "isin": {
    "market": "CA",
    "reason": "no ISIN found on issuer pages",
    "state": "not_on_record"
   },
   "jurisdiction": {
    "read_by": "GLEIF LEI record (LEI per the LEI column) · adjudicated by Claude",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://api.gleif.org/api/v1/lei-records/5299003IE70ITO2CBM73",
    "state": "filled",
    "value": "British Columbia"
   },
   "lei": {
    "read_by": "GLEIF name-exact",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://api.gleif.org/api/v1/lei-records/5299003IE70ITO2CBM73",
    "state": "sourced",
    "value": "5299003IE70ITO2CBM73"
   },
   "name": {
    "read_by": "tsx.com company directory (exchange list)",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://www.tsx.com/json/company-directory/search/tsx/^*",
    "state": "sourced",
    "value": "Fennec Pharmaceuticals Inc."
   },
   "sector": {
    "read_by": "TMX listed-companies workbook (exchange list, monthly; data month named in the source column)",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://www.tsx.com/en/resource/571 (tsx-and-amp-tsxv-listed-companies-2026-08-14-en.xlsx, data as of 31-Jul-2026)",
    "state": "sourced",
    "value": "Life Sciences"
   },
   "security_type": {
    "read_by": "TMX listed-companies workbook (exchange list, monthly; data month named in the source column)",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://www.tsx.com/en/resource/571 (tsx-and-amp-tsxv-listed-companies-2026-08-14-en.xlsx, data as of 31-Jul-2026)",
    "state": "sourced",
    "value": "Corporate"
   },
   "segment": {
    "market": "CA",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "tsx.com company directory (exchange list)",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://www.tsx.com/json/company-directory/search/tsx/^*",
    "state": "sourced",
    "value": "FRX"
   },
   "website": {
    "market": "CA",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": [],
   "domicile_change": [],
   "listing": [],
   "name_change": [],
   "segment_move": []
  },
  "market": "CA",
  "node": "ca-cm-kg",
  "numbers_hash": "sha256:7d255e2381a488879c37d4937f0da8952649877c9d03820ff1d2bbccd8b9b750",
  "open_research": {
   "rows": [],
   "state": "not_read"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [
    "Paragraph (o) of the definition",
    "Paragraph (q) of the definition"
   ],
   "outcomes": {
    "Paragraph (o) of the definition": {
     "determinable": true,
     "signal": "ACM-200"
    },
    "Paragraph (q) of the definition": {
     "determinable": true,
     "signal": "ACM-200"
    }
   },
   "read": {
    "basis": "one live read per instrument class, halt state and client category on this market; this issuer's group",
    "chapter": "https://mcp.ca-cm-kg.ai/book/aio.json",
    "door": "https://mcp.ca-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "rule_version": "acm-68000/ca/kyp-know-your-product-ni-31-103/r1",
   "section": "ca.aio.v11"
  },
  "record": {
   "as_of": "2026-11-06",
   "url": "https://mcp.ca-cm-kg.ai/record/TSX/FRX",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-08",
   "source": "https://iiroc.mediaroom.com/index.php?s=2429&l=100",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:7d255e2381a488879c37d4937f0da8952649877c9d03820ff1d2bbccd8b9b750",
 "path": "/ca/TSX/FRX",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "Fennec Pharmaceuticals Inc. is listed on the TSX under ticker FRX, with LEI 5299003IE70ITO2CBM73; no ISIN is on the record. The security type is Corporate, the sector is Life Sciences, and the jurisdiction is British Columbia. The segment is not on the record. The issuer is listed, not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 16 filings in the twelve months to 2026-11-06, across 12 filing days, all of them newswire releases. The median gap between filing days is 13 days. The latest filing is dated 2026-11-06, a newswire release, and is 0 days before the record date. The TSX median cadence gap is 16 days across 2,270 issuers, with a median of 0.0 filings and a median latency of 3.0 days. The Life Sciences median cadence gap is 17.5 days across 200 issuers, with a median of 7.0 filings and a median latency of 14 days.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor of record is Haskell & White LLP; its location is not on the record. The record holds no auditor changes.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The record holds no listing, delisting, name change, domicile change or segment move events. The halt flag is listed, not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "Under rule version acm-68000/ca/kyp-know-your-product-ni-31-103/r1, the outcome for the client category Paragraph (o) of the definition is signal ACM-200, determinable. The outcome for the client category Paragraph (q) of the definition is signal ACM-200, determinable. The chapter is as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "The field has not been read, so the number of research houses named on the issuer's investor-relations page is not on the record.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "The field has not been read, so the count of openly published research notes is not on the record.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The record holds no sealed vintage for this market, and no sealed issuer years are on the record. The live record began on 2026-09-10. Years 2021 through 2026 are sealed in the store but not served as of a date; the as-of door answers not_sealed.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "8 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://www.tsx.com/json/company-directory/search/tsx/^*"
  },
  {
   "for": "identity.jurisdiction",
   "source": "https://api.gleif.org/api/v1/lei-records/5299003IE70ITO2CBM73"
  },
  {
   "for": "identity.sector",
   "source": "https://www.tsx.com/en/resource/571"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.ca-cm-kg.ai/events/TSX/FRX"
  },
  {
   "for": "the halt flag",
   "source": "https://iiroc.mediaroom.com/index.php?s=2429&l=100"
  },
  {
   "for": "the auditor",
   "source": "https://www.sec.gov/Archives/edgar/data/1211583/000114420417029188/v467708_def14a.htm"
  },
  {
   "for": "the orderability chapter",
   "source": "https://mcp.ca-cm-kg.ai/book/aio.json"
  },
  {
   "for": "the record",
   "source": "https://mcp.ca-cm-kg.ai/record/TSX/FRX"
  }
 ],
 "title": "Fennec Pharmaceuticals Inc. (FRX) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}